Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. Founded by Bruce Booth and Nello Mainolfi in 2017, Kymera Therapeutics is backed by investors that include BlackRock, Redmile Group, Bessemer Venture Partners, MRL Ventures Fund, and Atlas Venture and is headquartered in Cambridge.